VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LKFT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LKFTLakefront Biotherapeutics N.V.
$34.39$2.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
LKFT logo

Lakefront Biotherapeutics N.V.

LKFT
NASDAQ · Immunology Biotech
$34.39
At close - Nov 17, 4:00 PM EST - USD
Market Cap$2.25B
P/E2.6x
52W High$36.24
Volume241.18K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Revenue Volatility Masks Structural Clinical Burn Risk

Galapagos N.V. faces a precarious transition as it pivots toward early-stage oncology, with its financial health heavily dependent on non-recurring milestone payments rather than sustainable commercial product demand.

GrowthContracting
ProfitabilityNegative
ValuationAttractive
TechnicalsStrong
Explore valuation models
MARKET ACTION

LKFT price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

8/12 Beats

EPS beat 8 of last 12 quarters

02

Valuation risk

-93% Peers

P/E is 93% below peer median

03

Market leadership

RS 80 · Leader

High momentum (Outperforming 80% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Feb 11

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
LKFT+4.31%
S&P 500 (^GSPC)+7.21%
1-Year Return
LKFT+11.80%
S&P 500 (^GSPC)+10.03%
3-Year Return
LKFT-8.32%
S&P 500 (^GSPC)+58.95%
5-Year Return
LKFT-32.78%
S&P 500 (^GSPC)+57.84%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
2.6x
Forward P/E
N/A
EV/EBITDA100th %ile
4.0x
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
2.6x
12.7x
0th· Low
EV/EBITDA
4.0x
3.7x
100th· High
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$131.23+281.6%
Base (Fair)$184.52+560.7%
Bull$293.34+753.0%
$131.23 Bear$184.52 Base$293.34 Bull
Current Market Price: $34.39
Trades at a 81.4% discount to Base DCF ($184.52)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$1.11B+303.5% YoY
Net income FY25
$321M+333.1% YoY
Free cash flow FY25
-$271M
Operating margin FY25
45.1%+113.4 pts YoY
ROIC (FY25)11.8%
Avg ROIC 5Y-7%
ROE (TTM)24.4%
Piotroski Score6 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate8/12 (67%)
Revenue Beat Rate7/12 (58%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 11, 2026
-$0.04+87.9%
vs -$0.37
$8M+43.1%
vs $6M
Q3 2026
Aug 10, 2026
$0.03+104.2%
vs -$0.82
$14M+125.7%
vs $6M
Q2 2026
May 6, 2026
$0.25+126.2%
vs -$0.94
$8M-20.4%
vs $10M
Q1 2026
Feb 23, 2026
$13.90+11077.7%
vs -$0.13
$1.0B+1166.2%
vs $83M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Globe News Wire·2d ago
Lakefront start nieuw aandeleninkoopprogramma ter waarde van €50 miljoen na voltooiing van initieel aandeleninkoopprogramma

Mechelen, België; 16 november 2026, 7. 30 CET; gereglementeerde informatie - Lakefront Biotherapeutics NV (Euronext and NASDAQ: LKFT) heeft vandaag de start aangekondigd van een nieuw aandeleninkoopprogramma ter waarde van maximaal €50 miljoen, na de voltooiing van het initiële programma van €50 miljoen dat op 9 juni 2026 werd aangekondigd.

GlobeNewsWire·2d ago
Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program

Mechelen, Belgium; November 16, 2026; 7.30 AM CET regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the initiation of a new share repurchase program of up to €50 million, following completion of its initial €50 million program announced on June 9, 2026.

GlobeNewsWire·6d ago
Lakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business Update

Gamgertamig poster accepted for presentation at the 2026 ASH 1 Annual Meeting, featuring data from ongoing Phase 1b studies that suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an “immune reset”

GlobeNewsWire·Nov 10, 2026
Lakefront to Present at the 2026 Jefferies Global Healthcare Conference in London

Mechelen, Belgium; November 10, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the 2026 Jefferies Global Healthcare Conference in London at 2:00 pm GMT (9:00 am ET) on Tuesday, November 17, 2026.

Filtered for Lakefront Biotherapeutics N.V.More Headlines
04

Compare before deciding

Benchmark LKFT against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Lakefront Biotherapeutics N.V. (LKFT)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
LKFT logoLKFTLakefront Biotherapeutics N.V.Current
$34.39$2.25B2.58303.5%85.88%24.44%—
ARCT logoARCTArcturus Therapeutics Holdings Inc.
$7.97$226.53M-2.90-51.43%-312.88%-41.86%—
ACAD logoACADACADIA Pharmaceuticals Inc.
$18.32$3.14B8.8711.87%30.13%28.03%—
HALO logoHALOHalozyme Therapeutics, Inc.
$95.97$11.38B24.2437.55%26.93%544.26%—
EXEL logoEXELExelixis, Inc.
$68.50$17.22B19.796.98%35.45%45.54%—
IONS logoIONSIonis Pharmaceuticals, Inc.
$26.96$4.48B-8.2033.87%-56.9%-120.44%—

Compare LKFT vs Peers

Lakefront Biotherapeutics N.V. (LKFT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ARCT

Most directly comparable listed peer for LKFT.

Scale Benchmark

vs LLY

Larger-name benchmark to compare LKFT against a more recognizable public peer.

Peer Set

Compare Top 5

vs ARCT, ACAD, HALO, EXEL

Get notified when LKFT posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

LKFT Frequently Asked Questions

Lakefront Biotherapeutics N.V. (LKFT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Lakefront Biotherapeutics N.V.'s revenue?

Lakefront Biotherapeutics N.V. (LKFT) reported $927.0M in revenue over the trailing twelve months. Revenue was $1.11B in fiscal year 2025. That is 14202% more than the $7.8M of fiscal year 2004.

How fast is Lakefront Biotherapeutics N.V. growing?

Lakefront Biotherapeutics N.V. (LKFT) grew revenue by 223.1% over the trailing twelve months, compared with the twelve months before.

Is LKFT profitable?

Yes. Lakefront Biotherapeutics N.V. (LKFT) earned $796.1M in net income over the trailing twelve months (a 85.9% net margin).

Dividend & Returns
What is LKFT's return on equity?

Lakefront Biotherapeutics N.V. (LKFT) had a return on equity (ROE) of 24.4% over the trailing twelve months. That is well above the market's typical 10-15%.

What is Lakefront Biotherapeutics N.V.'s free cash flow?

Lakefront Biotherapeutics N.V. (LKFT) had negative free cash flow of $165.0M over the trailing twelve months.

What if you invested $1,000 in LKFT back in 2004?

Total return calculator · dividends reinvested · 22+ years of data

See returns →